17.05.2016
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 AG: Management Board at Vita34 AG expanded with Director of Sales and Marketing
DGAP-News: Vita 34 AG / Key word(s): Change of Personnel
Vita 34 AG: Management Board at Vita34 AG expanded with Director of Sales
and Marketing
17.05.2016 / 18:08
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Management Board at Vita34 AG expanded with Director of Sales and Marketing
Leipzig, May 17, 2016 - The Supervisory Board of Vita 34 AG (WKN A0BL84)
has appointed Dr. Wolfgang Knirsch as Director of Sales and Marketing
effective June 1, 2016. The growth strategy at Vita 34 will be strengthened
sustainably by the appointment of Dr. Knirsch.
The market-leading position of the company in the German-speaking countries
is to be persistently expanded, and additional market share in Europe won.
The company enters new growth markets in Europe by means of expansion via
local cooperative sales efforts. In addition, Vita 34 plans on establishing
and operating umbilical cord blood banks in selected growth markets in Asia
and Latin America together with partners. Vita 34 taps potential profits in
new markets via geographic diversification, lending the entire business
model additional and sustainable stability.
The new Sales Director is taking the position with the goal of tapping the
existing potential in markets that Vita 34 AG is already active in via
focused and efficient measures and, in addition, to identify and establish
additional markets.
Dr. Knirsch will take responsibility for the Sales and Marketing
departments as of June 1, 2016. The other departmental responsibilities
will remain the same. Dr. André Gerth, the CEO, is responsible for
Strategy, Production, and Research & Development. Mr. Falk Neukirch, the
CFO, is responsible for Finance, Human Resources, Legal, Investor
Relations, IT, and Purchasing.
Dr. Hans-Georg Giering, Supervisory Board Chairman: "I am very pleased that
we have been successful in bringing on Dr. Knirsch as a member of the Vita
34 Management Board. His marketing and sales experience in and around
Biotechnology for significant companies will give Vita 34 an additional
development boost. Dr. Knirsch has a brand and long track record in the
efficient cultivation and development of national and international
markets, in particular with regard to specialty and niche products.
Following his doctorate in inorganic chemistry at RWTH Aachen, Dr. Knirsch
began his professional career in the sales team at Hoechst AG.
Subsequently, he successfully led various national and international
marketing and sales departments, as well as business development
departments there, at Merck KGaA, and finally at Biotest AG. Apart from
other indications, during this time he gathered comprehensive knowledge of
the fields of haemato-oncology, gynecology and obstetrics. In his last
position, Dr. Knirsch was responsible at Biotest AG for international
sales, where he persistently boosted sales and profit through the
consistent implementation of marketing and sales strategies with
cooperation partners worldwide.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood. The basis for its
successful work is an outstanding position in the technological segment of
cryo-preservation. Here, cells and tissue are preserved alive at some
-190ºC for long periods of time, and can be used if needed in the context
of medical treatment. More than 145,000 families are already taking
advantage of this offering and have provided for their children with a stem
cell deposit at Vita 34.
---------------------------------------------------------------------------
17.05.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart
End of News DGAP News Service
---------------------------------------------------------------------------
464383 17.05.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V